UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000016063
Receipt number R000018664
Scientific Title The study about the prevalence of olfactory dysfunction related to allergic rhinitis and the effect by montelukast
Date of disclosure of the study information 2014/12/27
Last modified on 2023/01/02 09:56:04

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The study about the prevalence of olfactory dysfunction related to allergic rhinitis and the effect by montelukast

Acronym

The study about the effects on olfactory dysfunction by montelukast

Scientific Title

The study about the prevalence of olfactory dysfunction related to allergic rhinitis and the effect by montelukast

Scientific Title:Acronym

The study about the effects on olfactory dysfunction by montelukast

Region

Japan


Condition

Condition

allergic rhinitis

Classification by specialty

Oto-rhino-laryngology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The study about the prevalence of oflactory dysfunction related to allergic rhinitis and the effects on olfactory dysfunction by montelukast

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

The prevalence of patinets with olfactory dysfunction related to alergic rhinitis

The improvement of olfactory dysfunction

Key secondary outcomes

The improvement nasal symptoms related to allergic rhinitis


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

15 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with allergic rhinitis and olfactory dysfunction

Key exclusion criteria

Patients with other nasal disease such as nasal polyp, severe nasal septim deviation, and infectious upper airway disease
Patienst with non-allergic rhinitis
Patients who are treated by medicines that affects nasal condition.
Patients who are already treated on specific immunotherapy
Patients who had been treatedby laser turbinectomy
Patients who are already treated by allergic medicine such as steroid because of other allergic disease
lactating or pregnancy women
Patients whoom doctor decide as unappropriate for the study

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Shigeharu
Middle name
Last name Fujieda

Organization

University of Fukui

Division name

Department of Otorhinolaryngology Head & Neck Surgery, Faculty of Medical Sciences

Zip code

9101193

Address

23 Shimoaizuki, Matsuoka, Yoshida, Fukui, Japan

TEL

0776-61-8407

Email

sfujieda@u-fukui.ac.jp


Public contact

Name of contact person

1st name Yoshimasa
Middle name
Last name Imoto

Organization

University of Fukui

Division name

Department of Otorhinolaryngology Head & Neck Surgery, Faculty of Medical Sciences

Zip code

9101193

Address

23 Shimoaizuki, Matsuoka, Yoshida, Fukui, Japan

TEL

0776-61-8407

Homepage URL


Email

yimoto@u-fukui.ac.jp


Sponsor or person

Institute

University of Fukui

Institute

Department

Personal name



Funding Source

Organization

Kyorin Pharmaceutical Company

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

University of Fukui

Address

23-3, Shimoaizuki, Matsuoka, Eiheiji, Yoshida-gun, Fukui, Japan

Tel

0776-61-3111

Email

chiken@ml.cii.u-fukui.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

京都府立医科大学病院(京都府)、京都第二赤十字病院(京都府)、日赤和歌山医療センター(和歌山県)、済生会中津病院(大阪府)、関西医科大学病院(大阪府)、関西医科大学香里病院(大阪府)、わたなべ耳鼻咽喉科アレルギークリニック(広島)、福井大学病院(福井県)、公立丹南病院福井県)、福井社会保険病院福井県)、福井総合病院福井県)、国立機構福井病院福井県)、舞鶴共済病院福井県)、市立三国病院福井県)、笠原病院福井県)、斎藤病院福井県)


Other administrative information

Date of disclosure of the study information

2014 Year 12 Month 27 Day


Related information

URL releasing protocol

https://center6.umin.ac.jp/rd/rd.cgi?t=ic&n=R000018664&k=3004HqIkRXvNiZsoz2PDwbmS

Publication of results

Unpublished


Result

URL related to results and publications

https://center6.umin.ac.jp/rd/rd.cgi?t=ic&n=R000018664&k=3004HqIkRXvNiZsoz2PDwbmS

Number of participants that the trial has enrolled

50

Results

Patients treated for allergic rhinitis with anti-leukotriene showed improvement in symptoms of nasal congestion, as well as hyposmia.

Results date posted

2023 Year 01 Month 02 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Seasonal and perennial allergic rhinitis patients, including Japanese cedar pollinosis patients

Participant flow

Anti-leukotriene drugs were prescribed to patients who showed symptoms related to allergic rhinitis and visited outpatient clinics, for those who gave consent.

Adverse events

none

Outcome measures

Symptoms related to allergic rhinitis such as sneezing, rhinorrhea, and nasal congestion, as well as hyposmia.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2012 Year 07 Month 19 Day

Date of IRB

2012 Year 07 Month 19 Day

Anticipated trial start date

2012 Year 07 Month 19 Day

Last follow-up date

2014 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

The nasal symptoms an olfactory dysfunctionrelated to allergic rhinitis were measured by visual analog scare (VAS) before and after administratio of montelukast.


Management information

Registered date

2014 Year 12 Month 26 Day

Last modified on

2023 Year 01 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018664


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name